Exenatide improves hypertension in a rat model of the metabolic syndrome

Kevin D. Laugero, Anthony H. Stonehouse, Stacy Guss, Jannine Landry, Calvin Vu, David G. Parkes

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Exenatide is a peptide incretin mimetic that has glucoregulatory actions associated with weight reduction. Previous reports demonstrated acute increases in blood pressure after systemic or intracerebroventricular administration of exenatide or glucagon like peptide 1 (GLP 1) in rats. However, there are limited studies testing the chronic effects of these peptides on arterial pressure and no reports showing the effects of these peptides to reverse hypertension in the context of the metabolic syndrome. Methods: Thus, we examined the response to peripheral exenatide using telemetry in conscious, unrestrained rats under normotensive conditions and in a model of hypertension/metabolic syndrome induced by corticosterone. Rats were implanted with either corticosterone or wax (control) pellets, followed 14 days later by the additional implantation of pumps to deliver exenatide (1 μg/kg per day) or vehicle for 7 days. Results: The 21-day corticosterone treatment produced hypertriglyceridemia, visceral fat deposition, hyperglycemia, insulin resistance, and an elevation of mean arterial blood pressure (MAP) by 14 ± 1 mmHg. Exenatide significantly reversed corticosterone-induced increases in blood pressure and this normalization occurred independently from change in body weight. Additionally, exenatide reduced MAP by 5 ± 3 mmHg in normotensive control rats. Conclusions: These results are the first demonstration of a durable antihypertensive effect of exenatide in a glucocorticoid-induced model of the metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalMetabolic Syndrome and Related Disorders
Volume7
Issue number4
DOIs
StatePublished - Aug 1 2009

Fingerprint

Hypertension
Arterial Pressure
Corticosterone
Peptides
Blood Pressure
Incretins
Telemetry
Body Weight Changes
Glucagon-Like Peptide 1
Intra-Abdominal Fat
Waxes
Hypertriglyceridemia
exenatide
Hyperglycemia
Antihypertensive Agents
Glucocorticoids
Insulin Resistance
Weight Loss
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Laugero, K. D., Stonehouse, A. H., Guss, S., Landry, J., Vu, C., & Parkes, D. G. (2009). Exenatide improves hypertension in a rat model of the metabolic syndrome. Metabolic Syndrome and Related Disorders, 7(4), 327-333. https://doi.org/10.1089/met.2008.0095

Exenatide improves hypertension in a rat model of the metabolic syndrome. / Laugero, Kevin D.; Stonehouse, Anthony H.; Guss, Stacy; Landry, Jannine; Vu, Calvin; Parkes, David G.

In: Metabolic Syndrome and Related Disorders, Vol. 7, No. 4, 01.08.2009, p. 327-333.

Research output: Contribution to journalArticle

Laugero, KD, Stonehouse, AH, Guss, S, Landry, J, Vu, C & Parkes, DG 2009, 'Exenatide improves hypertension in a rat model of the metabolic syndrome', Metabolic Syndrome and Related Disorders, vol. 7, no. 4, pp. 327-333. https://doi.org/10.1089/met.2008.0095
Laugero, Kevin D. ; Stonehouse, Anthony H. ; Guss, Stacy ; Landry, Jannine ; Vu, Calvin ; Parkes, David G. / Exenatide improves hypertension in a rat model of the metabolic syndrome. In: Metabolic Syndrome and Related Disorders. 2009 ; Vol. 7, No. 4. pp. 327-333.
@article{bd32ad22251341688c330110a6817eb8,
title = "Exenatide improves hypertension in a rat model of the metabolic syndrome",
abstract = "Background: Exenatide is a peptide incretin mimetic that has glucoregulatory actions associated with weight reduction. Previous reports demonstrated acute increases in blood pressure after systemic or intracerebroventricular administration of exenatide or glucagon like peptide 1 (GLP 1) in rats. However, there are limited studies testing the chronic effects of these peptides on arterial pressure and no reports showing the effects of these peptides to reverse hypertension in the context of the metabolic syndrome. Methods: Thus, we examined the response to peripheral exenatide using telemetry in conscious, unrestrained rats under normotensive conditions and in a model of hypertension/metabolic syndrome induced by corticosterone. Rats were implanted with either corticosterone or wax (control) pellets, followed 14 days later by the additional implantation of pumps to deliver exenatide (1 μg/kg per day) or vehicle for 7 days. Results: The 21-day corticosterone treatment produced hypertriglyceridemia, visceral fat deposition, hyperglycemia, insulin resistance, and an elevation of mean arterial blood pressure (MAP) by 14 ± 1 mmHg. Exenatide significantly reversed corticosterone-induced increases in blood pressure and this normalization occurred independently from change in body weight. Additionally, exenatide reduced MAP by 5 ± 3 mmHg in normotensive control rats. Conclusions: These results are the first demonstration of a durable antihypertensive effect of exenatide in a glucocorticoid-induced model of the metabolic syndrome.",
author = "Laugero, {Kevin D.} and Stonehouse, {Anthony H.} and Stacy Guss and Jannine Landry and Calvin Vu and Parkes, {David G.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1089/met.2008.0095",
language = "English (US)",
volume = "7",
pages = "327--333",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Exenatide improves hypertension in a rat model of the metabolic syndrome

AU - Laugero, Kevin D.

AU - Stonehouse, Anthony H.

AU - Guss, Stacy

AU - Landry, Jannine

AU - Vu, Calvin

AU - Parkes, David G.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Exenatide is a peptide incretin mimetic that has glucoregulatory actions associated with weight reduction. Previous reports demonstrated acute increases in blood pressure after systemic or intracerebroventricular administration of exenatide or glucagon like peptide 1 (GLP 1) in rats. However, there are limited studies testing the chronic effects of these peptides on arterial pressure and no reports showing the effects of these peptides to reverse hypertension in the context of the metabolic syndrome. Methods: Thus, we examined the response to peripheral exenatide using telemetry in conscious, unrestrained rats under normotensive conditions and in a model of hypertension/metabolic syndrome induced by corticosterone. Rats were implanted with either corticosterone or wax (control) pellets, followed 14 days later by the additional implantation of pumps to deliver exenatide (1 μg/kg per day) or vehicle for 7 days. Results: The 21-day corticosterone treatment produced hypertriglyceridemia, visceral fat deposition, hyperglycemia, insulin resistance, and an elevation of mean arterial blood pressure (MAP) by 14 ± 1 mmHg. Exenatide significantly reversed corticosterone-induced increases in blood pressure and this normalization occurred independently from change in body weight. Additionally, exenatide reduced MAP by 5 ± 3 mmHg in normotensive control rats. Conclusions: These results are the first demonstration of a durable antihypertensive effect of exenatide in a glucocorticoid-induced model of the metabolic syndrome.

AB - Background: Exenatide is a peptide incretin mimetic that has glucoregulatory actions associated with weight reduction. Previous reports demonstrated acute increases in blood pressure after systemic or intracerebroventricular administration of exenatide or glucagon like peptide 1 (GLP 1) in rats. However, there are limited studies testing the chronic effects of these peptides on arterial pressure and no reports showing the effects of these peptides to reverse hypertension in the context of the metabolic syndrome. Methods: Thus, we examined the response to peripheral exenatide using telemetry in conscious, unrestrained rats under normotensive conditions and in a model of hypertension/metabolic syndrome induced by corticosterone. Rats were implanted with either corticosterone or wax (control) pellets, followed 14 days later by the additional implantation of pumps to deliver exenatide (1 μg/kg per day) or vehicle for 7 days. Results: The 21-day corticosterone treatment produced hypertriglyceridemia, visceral fat deposition, hyperglycemia, insulin resistance, and an elevation of mean arterial blood pressure (MAP) by 14 ± 1 mmHg. Exenatide significantly reversed corticosterone-induced increases in blood pressure and this normalization occurred independently from change in body weight. Additionally, exenatide reduced MAP by 5 ± 3 mmHg in normotensive control rats. Conclusions: These results are the first demonstration of a durable antihypertensive effect of exenatide in a glucocorticoid-induced model of the metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=68549090728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549090728&partnerID=8YFLogxK

U2 - 10.1089/met.2008.0095

DO - 10.1089/met.2008.0095

M3 - Article

C2 - 19320558

AN - SCOPUS:68549090728

VL - 7

SP - 327

EP - 333

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 4

ER -